ARTICLEhttps://harbor.dev.pubfactory.com/view/journals/asn/30/1/article-p33.xmlThe MEK Inhibitor Trametinib Ameliorates Kidney Fibrosis by Suppressing ERK1/2 and mTORC1 Signaling2021-02-18https://harbor.dev.pubfactory.com/view/journals/asn/30/1/article-p33.pdf2021-02-18The MEK Inhibitor Trametinib Ameliorates Kidney Fibrosis by Suppressing ERK1/2 and mTORC1 Signalinghttps://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-pxvi.xmlNCCN News2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-pxvi.pdf2026-04-18NCCN Newshttps://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-pxxxi.xmlReviewer Page2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-pxxxi.pdf2026-04-18Reviewer Pagehttps://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1411.xmlAn Oncologist's Letter to Santa: Bring Me Drugs!2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1411.pdf2026-04-18An Oncologist's Letter to Santa: Bring Me Drugs!https://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-pxxviii.xmlOncology Research Program2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-pxxviii.pdf2026-04-18Oncology Research Programhttps://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1429.xmlNCCN Guidelines Insights: Thyroid Carcinoma, Version 2.20182026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1429.pdf2026-04-18NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018https://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1424.xmlPathologic Complete Response in a Large Gastric GIST: Using Molecular Markers to Achieve Maximal Response to Neoadjuvant Imatinib2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1424.pdf2026-04-18Pathologic Complete Response in a Large Gastric GIST: Using Molecular Markers to Achieve Maximal Response to Neoadjuvant Imatinibhttps://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1421.xmlIn Memoriam: Arti Hurria, MD2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1421.pdf2026-04-18In Memoriam: Arti Hurria, MDhttps://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1418.xmlLetter to the Editor: Could Immunogenicity of Kaposi Sarcoma Be More Linked to Viral Antigens Than to the Tumor Mutational Burden?2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1418.pdf2026-04-18Letter to the Editor: Could Immunogenicity of Kaposi Sarcoma Be More Linked to Viral Antigens Than to the Tumor Mutational Burden?https://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1442.xmlMetastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1442.pdf2026-04-18Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1481.xmlImpact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naïve Prostate Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1481.pdf2026-04-18Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naïve Prostate Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1468.xmlComparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1468.pdf2026-04-18Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinomahttps://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1460.xmlNew Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1460.pdf2026-04-18New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendationshttps://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1451.xmlDelays in Diagnosis and Treatment of Breast Cancer: A Safety-Net Population Profile2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1451.pdf2026-04-18Delays in Diagnosis and Treatment of Breast Cancer: A Safety-Net Population Profilehttps://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1500.xmlSystemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1500.pdf2026-04-18Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncologyhttps://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1491.xmlVariation in Integrated Head and Neck Cancer Care: Impact of Patient and Hospital Characteristics2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1491.pdf2026-04-18Variation in Integrated Head and Neck Cancer Care: Impact of Patient and Hospital Characteristicshttps://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1539.xmlDo All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1539.pdf2026-04-18Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?https://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1547.xmlAnti-EGFR Therapy in Right-Sided Metastatic Colorectal Cancer: Right or Wrong?2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/16/12/article-p1547.pdf2026-04-18Anti-EGFR Therapy in Right-Sided Metastatic Colorectal Cancer: Right or Wrong?https://harbor.dev.pubfactory.com/view/journals/jnccn/16/suppl_1/article-pS5.xmlUse of Novel Combination Therapies in the Treatment of Advanced HR+/HER2− Breast Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/16/suppl_1/article-pS5.pdf2026-04-18Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2− Breast Cancer